Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: U071- COVID 19 virus identified
Conditions
Interventions
Intervention1: LifeViroTreat: Chlorine 1mg/m3 Every 4 Hours for 5 days
Control Intervention1: Purified Water 10 ml: Purified Water 10 ml
Control Intervention2: Purified Water 10 ml: Purified Water 10
Sponsors
Supreme Drugs Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patient with RT-PCR positive for nCOVID-19 within last 72 hours with Ct value > 17. 2. Male and female patients with age above 18 years and below 65 years of age. 3. Patient with ARVI score atleast 2 or more. 4. Patient willing to provide informed consent to participate into the trial. 5. Patient able to complied requirement of study and protocol. 6. Patient with SpO2 > 94 %, Respiratory rate
Exclusion criteria
Exclusion criteria: 1. Known hypersensitivity or idiosyncratic reaction to Chlorine or any of related substance or ingredient of the formulation. 2. Patient having past history of respiratory disorder like COPD, Asthma etc. 3. Patient is on medication before tested nCOVID 19 positive for respiratory disease or disorder (other than viral infection). 4. Patient was on immunomodulatory drug. 5. Patient who has participated in other clinical study related to nCOVID 19. 6. Patients with other severe acute or chronic conditions that may increase the risk of participation in the study and study treatment, or may interfere with interpretation of study results, and judged by the investigator as not suitable for participation in this clinical trial.. 7. Patients who are diagnosed and/or on treatment for venous thromboembolism, ischemic heart disease, myocardial infarction, congestive cardiac failure, unexplained vaginal bleeding with suspicion of serious underlying condition, history of breast or cervical cancer, malignant tumor. 8. Patient of Hypertension and/or Diabetes who was not on stable treatment in past 3 month. 9. Known history of Chronic Kidney disease. 10. Known history of Chronic Liver disease. 11. Reports of any history of malignancy. 12. Nursing mother or pregnant women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| At least decrease in Ordinal Scale by 1 pointTimepoint: Day 4, Day 6 | — |
Secondary
| Measure | Time frame |
|---|---|
| CGI-I and CGI-S assessment Change in ordinal scale from baseline Proportion of patient require Oxygen Proportion of patient require hospitalization Change in ARVI score Proportion of patient with resolution of ARVI score Change in CRP, D-Dimer All -cause mortality Change from baseline in log Viral load Time to alleviation of flu like nonspecific symptoms Time to alleviation of Nasal/Throat/Chest specific symptoms Time to alleviate loss of appetite symptom Proportion of patient withdrawn from treatment Proportion of patient drop out from treatment Comparison of Adverse Event Timepoint: Day 4, Day 6 and Day 14 | — |
Countries
India
Contacts
Public ContactDr Nilesh Patel
Panexcell Clinical Lab Pvt Ltd
Outcome results
None listed